When was Empros Pharma founded?

Empros Pharma was founded in 2013.

Where is Empros Pharma located?

Empros Pharma is headquartered in Solna, Sweden.

Who is the current CEO of Empros Pharma?

Arvid Soderhall of Empros Pharma.

How many employees does Empros Pharma have?

As of Apr 30, 2026, the latest employee count at Empros Pharma is 9.

Is Empros Pharma a funded company?

Empros Pharma is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Empros Pharma rank among its competitors?

Empros Pharma ranks 125th amongst 149 active competitors, of which 52 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Congruence Therapeutics, which secured $39.5M in Mar, 2026.

Who are the top competitors of Empros Pharma?

Empros Pharma's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Among them, Congruence Therapeutics secured the most recent funding round in March, 2026.

Empros Pharma - 2026 Company Profile, Team, Funding & Competitors

Company Details

Empros Pharma is involved in the development of the drug for overweight and obesity treatment. The company leading candidate EMP16 is in the late-stage clinical trials. The drug helps in improving blood glucose level by delaying normal food digestion and absorption processes towards the end of the small intestine and its also enhance the various endogenous hormone response for different physiological activity.

Website: emprospharma.com
Email ID: *****@emprospharma.com
Phone Number: +46 **********

Key Metrics

Founded Year

2013

Location

Solna, Sweden

Stage

Funding Raised

Investors

Flerie

Ranked

125^th among 149 active competitors

Employee Count

9 as on Apr 30, 2026

Similar Companies

Adocia & 92 more

View Empros Pharma's full profile

Empros Pharma is a funded company. Empros Pharma has 1 institutional investor.

View details of Empros Pharma's funding rounds and investors

The founders of Empros Pharma are Anders Forslund and Ulf Holmback. Arvid Soderhall is the CEO of Empros Pharma.

Here are the details of Empros Pharma's key team members:

Anders Forslund: Founder & CMO of Empros Pharma.
Ulf Holmback: Founder of Empros Pharma.
Arvid Soderhall: CEO of Empros Pharma.
Contact Info: 1 email address

View details of Empros Pharma's Founder profiles and Board Members

Empros Pharma's employee count trend

Empros Pharma has 9 employees as of Apr 26. Here is Empros Pharma's employee count trend over the years:

Uncover Empros Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Empros Pharma include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Here is the list of Top 10 competitors of Empros Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
3rd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
4th	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, BioBrit & 7 others	68/100
5th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	ATW Partners, Orbimed & 5 others	65/100
6th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Orbimed, Longitude Capital & 3 others	64/100
7th	Rani Therapeutics 2012, San Jose (United States), Public	Developer of technology for the oral delivery of large drug molecules	$226M	Cathay Financial Holdings, Shire & 18 others	63/100
8th	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Premji Invest, Kinnevik & 29 others	63/100
9th	Congruence Therapeutics 2021, Montreal (Canada), Series B	Developer of therapeutics for the treatment of rare diseases	$136M	Amplitude, Orbimed & 9 others	62/100
10th	BioAge Labs Emeryville (United States), Public	Provider of a bioinformatics platform for biomarkers and drug discovery	$294M	Andreessen Horowitz, Sofinnova Investments ... & 26 others	62/100
125th	Empros Pharma 2013, Solna (Sweden), Funding Raised	Developer of drug for overweight and obesity treatment	-	Flerie	24/100